What is Molecule?
Molecule operates as a platform designed to accelerate innovation within the pharmaceutical sector. It establishes a collaborative open market that connects scientists, patients, and industry stakeholders to foster drug development. The Molecule protocol facilitates the distributed research and development of pharmaceutical intellectual property, enabling IP creators to exchange partial ownership for access to liquidity, research, and funding. This model aims to distribute the inherent ownership, risk, and cost associated with drug development, thereby fostering new innovation and business models to deliver a wider array of inclusive treatments to patients.
How much funding has Molecule raised?
Molecule has raised a total of $13M across 1 funding round:
Angel/Seed
$13M
Angel/Seed (2022): $13M with participation from Backed, Northpond Ventures, Shine Capital, and Speedinvest
Key Investors in Molecule
Backed
Backed is a human-centric seed fund focused on supporting founders in frontier technology, with a particular emphasis on European venture. They invest early, typically between $500K and $5M, aiming to build generation-defining companies.
Northpond Ventures
Northpond Ventures is dedicated to advancing science and technology for significant human impact, focusing on breakthrough innovations and entrepreneurial ventures. They partner with innovators to drive meaningful change in the scientific landscape.
Shine Capital
Shine Capital is an early-stage venture capital firm that partners with determined entrepreneurs to create iconic businesses, providing capital and support to ambitious startups.
What's next for Molecule?
The substantial enterprise-level funding and recent strategic investment indicate Molecule is poised for significant scaling and further development of its open market protocol. This capital infusion is expected to enhance its capabilities in connecting key stakeholders in the pharmaceutical R&D ecosystem, potentially expanding its reach and impact on drug discovery and development. The company's focus on distributing ownership and risk suggests a strategic direction towards building a more inclusive and efficient model for bringing novel treatments to market, likely involving further platform enhancements and strategic partnerships.
See full Molecule company page
